26.1 C
New York
Monday, June 8, 2026

Tag: Italy

newssourceFORcompanyinformationcontent1marketreleases

Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveInsight

The outlook for the neuroblastoma treatment market is optimistic, fueled by progress in targeted therapies and immunotherapies. GD2-targeted immunotherapy is increasingly being incorporated into...

Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveInsight

The outlook for the neuroblastoma treatment market is optimistic, fueled by progress in targeted therapies and immunotherapies. GD2-targeted immunotherapy is increasingly being incorporated into...

Stone in Yunfu: carving timeless beauty through centuries of craftsmanship

GUANGZHOU, China, Aug. 14, 2025 /PRNewswire/ -- News report from GDToday. Yunfu, a city in Guangdong Province known as the "Capital of Stone in China," shines...

Stone in Yunfu: carving timeless beauty through centuries of craftsmanship

GUANGZHOU, China, Aug. 14, 2025 /PRNewswire/ -- News report from GDToday. ...

Erdem Hospital Performs First-of-Its-Kind Spinal Revision Surgery

Erdem Hospital’s first spinal revision surgery restores mobility to an Italian patient, ending years of paralysis and enabling her to walk again.

Whole Genome Sequencing Market to Reach New Heights by 2030

"With cutting-edge advances in next-generation sequencing and growing interest in personalized medicine, whole genome sequencing is set to transform disease diagnosis and treatment, driving...

Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications | DelveInsight

Over the last ten years, cell-based immunotherapy has emerged as a promising approach for treating solid tumors. Several companies, including Iovance Biotherapeutics, Obsidian Therapeutics,...

Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications | DelveInsight

Over the last ten years, cell-based immunotherapy has emerged as a promising approach for treating solid tumors. Several companies, including Iovance Biotherapeutics, Obsidian Therapeutics,...

FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

— Approximately 500,000 U.S. Patients Are Diagnosed with Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage — — BRINSUPRI 10...

AleAnna, Inc. Announces Receipt of Regional Approval for its Gradizza Field Development Project

This Milestone Represents the Final Approval Required Prior to Ministry Award of a Production Concession

SASOL LIMITED: TRADING STATEMENT FOR THE YEAR ENDED 30 JUNE 2025

JOHANNESBURG, Aug. 12, 2025 /PRNewswire/ -- We refer to the SENS announcement of 22 July 2025, on the release of the quarterly production and...

Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure

IBAT Inhibitors Market Witnesses Strong Growth During the Forecast Period (2025-2034) Owing to the Rising Demand for Rare Cholestatic Liver Disease Therapies | DelveInsight

The market for IBAT inhibitors is projected to experience significant growth in the near future, fueled by the rising incidence of genetic disorders, a...

IBAT Inhibitors Market Witnesses Strong Growth During the Forecast Period (2025-2034) Owing to the Rising Demand for Rare Cholestatic Liver Disease Therapies | DelveInsight

The market for IBAT inhibitors is projected to experience significant growth in the near future, fueled by the rising incidence of genetic disorders, a...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsItaly

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers